Market capitalization | $2.98b |
Enterprise Value | $5.59b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 1.99 |
P/S ratio (TTM) P/S ratio | 1.06 |
P/B ratio (TTM) P/B ratio | 0.93 |
Revenue growth (TTM) Revenue growth | -9.66% |
Revenue (TTM) Revenue | $2.81b |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
10 Analysts have issued a Quidel Corporation forecast:
10 Analysts have issued a Quidel Corporation forecast:
Sep '24 |
+/-
%
|
||
Revenue | 2,814 2,814 |
10%
10%
|
|
Gross Profit | 1,131 1,131 |
16%
16%
|
|
EBITDA | 559 559 |
25%
25%
|
EBIT (Operating Income) EBIT | 99 99 |
65%
65%
|
Net Profit | -1,867 -1,867 |
14,241%
14,241%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Quidel Corp. engages in the development, manufacture and market of rapid diagnostic testing solutions. Its portfolio includes rapid immunoassays, cardiac immunoassays, specialized diagnostic solutions and molecular diagnostic solutions. The products are directly sold to end users and distributors and for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies and wellness screening centers. The company was founded in 1979 and is headquartered in San Diego, CA.
Head office | United States |
CEO | Brian Blaser |
Employees | 7,100 |
Founded | 2022 |
Website | www.quidelortho.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.